Molecular Markers of Prognosis in Colorectal Cancer Patients
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- NCT00220142
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Brief Summary
To correlate the molecular profile of a series of defined CRCs with prognosis and toxicity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 103
Inclusion Criteria
- All patients participating in the RMHNHST study of infusional versus bolus 5FU (Saini et al. 2003).
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular markers are associated with prognosis in NCT00220142 colorectal cancer study?
How do molecular profiles correlate with toxicity outcomes in Royal Marsden CRC observational trial?
What biomarkers predict response to standard-of-care therapies in defined CRC subtypes?
Are there comparative studies on molecular markers for adverse event management in CRC patients?
What drug targets are identified through molecular profiling in colorectal cancer research?
Trial Locations
- Locations (1)
Royal Marsden Hospital
🇬🇧Sutton, Surrey, United Kingdom
Royal Marsden Hospital🇬🇧Sutton, Surrey, United Kingdom